WO1993021928A1 - Liquid glucose control solution and process of making the same - Google Patents
Liquid glucose control solution and process of making the same Download PDFInfo
- Publication number
- WO1993021928A1 WO1993021928A1 PCT/US1993/003799 US9303799W WO9321928A1 WO 1993021928 A1 WO1993021928 A1 WO 1993021928A1 US 9303799 W US9303799 W US 9303799W WO 9321928 A1 WO9321928 A1 WO 9321928A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glucose
- control solution
- concentration
- red blood
- blood cells
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
Definitions
- the present invention is directed generally to a glucose control solution for use in establishing the validity of dry reagent glucose test strips, and more particularly to a liquid glucose control suitable for use in glucose analyzer systems that give quantitative measures of glucose in blood or serum.
- the control solution includes water, a reaction-rate regulator, a gel which does not change viscosity with temperature, and glucose.
- the level of glucose in the blood is determined by the amount of carbohydrate ingested and by available insulin.
- the diabetic may produce either excess insulin and have an abnormally low blood glucose level or, insufficient insulin which will result in an abnormally high level of blood glucose. Both circumstances lead to serious health problems for the diabetic. Monitoring the level of glucose in the blood is therefore important to the management of diabetes.
- Dry reagent strips are widely used for detecting glucose in urine and blood.
- test strips comprise plastic strips provided at one end thereof with an absorbent paper portion impregnated with a detector system, e.g., an enzyme system and a color indicator compound which changes color when oxidized.
- the detector system is normally covered with a porous membrane filter.
- the change in r 3» color can be measured by comparing the strip to a color chart calibrated to various glucose concentrations.
- instruments have been developed to measure the color change in a reflectance photometer and thereby give quantitative results.
- One such instrument is commercially available from Diagnostic Laboratory Systems Division, Boehringer Mannheim corporation and is marketed under the name Accu-Chek ® EasyTM. This instrument is designed for use by diabetics so that they can monitor their blood glucose level.
- a primary object of the invention is to provide an improved liquid glucose control solution.
- Another object of the invention to provide a control solution with reaction kinetics providing rapid accurate readings stable over ninety seconds when used with a dry reagent strip.
- Another object of the invention is to provide a control solution that produces reproducible readings within a normal range of temperatures.
- the liquid glucose control solution of the present invention includes a stable liquid control solution including water, a predetermined amount of glucose, phosphate as an anionic component, and xanthan as a soluble gel.
- An alternative control solution may additionally include fixed red blood cells.
- Other materials such as a disinfectant may be mixed with the above four required components.
- Another aspect of the invention is a process of making the liquid glucose control solution by mixing the four required components together.
- Figure 1 is a graph showing the effect of different phosphate concentrations on the reaction kinetics resulting from use of the present invention.
- liquid glucose control solution of the present invention is designed to operate with an instrument called the Accu-Chek ® EasyTM, it will also operate with many other instruments.
- the objectives of the control are to provide reaction kinetics comparable to blood; to defuse or chromatograph like blood, and to give responses that are not temperature dependent.
- Any convenient method can be used to formulate the glucose reference control of the invention.
- One preferred procedure involves first making up an aqueous glucose solution by adding glucose to distilled water followed by the addition of the essential phosphate and xanthan components and any optimal components such as a disinfectant.
- Fixed red cells may also be added to the control as in Ryan, U.S. Patent No. 4,729,959.
- the water is used to create a reagent solution.
- predetermined means that, prior to formulation of the actual reagent, a concentration of glucose has been selected. This concentration may vary as will be recognized by those skilled in the art.
- Ryan U.S. Patent No.4,729,959 discloses a range of from 2.22 mM/Lto 27.8 mM/L, but lower ranges to about 1.11 mM/L are possible. A typical range would be from about 3.33 mM/L to 16.7 mM/L. The units expressed are millimolar per liter.
- Phosphate is included as a reaction rate regulator. It is desirable for the reaction to proceed rapidly and then plateau to a constant value. This pattern produces a result that is less time dependent. Thus, the meter can be read for example in 10 seconds or 60 seconds and the result will be the same.
- Figure 1 shows the reflectance values obtained at different times and the effect of phosphate ions on the process. As the phosphate is increased, lower initial reflectance values (more color) are attained. However, when 40 mM/LP0 4 is used, there is a decoloration that occurs with time. - 5 -
- the ideal concentration is the 20 mM/LP0 4 where the reflectance is constant with time.
- the sample with no P0 4 produces such a slow reaction, that equilibrium is not reached until 70 seconds have passed.
- a phosphate concentration of about 5 to 35 mM/L may be used with about 10 to 30 being more preferred and about 20 mM/L being most preferred. These concentrations of phosphate are best for glucose concentrations of 2.8 mM/L - 13.9 mM/L. At higher concentrations of glucose, more phosphate is required and less at lower concentrations.
- the glucose containing solution must move to the analysis system in a similar manner as blood.
- a thickening agent or gel be used.
- These agents include polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, dextran and bovine serum albumin. None of these agents provide any special characteristics except to make the solution viscous.
- polystyrene sulphonate is claimed as a viscosity agent. As in the above, this agent simply increases viscosity.
- the gel that is used in the present invention is xanthan, a polysaccharide. This provides special characteristics to the product.
- Xanthan unlike other gels, does not change viscosity with temperature.
- the viscosity of the solution containing xanthan gum experiences almost no change with temperatures upto93°C (200 ,, F).
- a change in viscosity produces erratic values and variation in results with temperature.
- this gel produces uniform chromatography or diffusion of the control. This provides greater precision as shown by the data of the following Table I.
- Table I shows that both the standard deviation and coefficient of variation were about tenfold less in the series of tests with xanthan as compared to the series of tests using the control solution without xanthan.
- Xanthan may be used in concentrations of about 1 to 5 g/1, more preferably 2 to 4 g/1 and optimally about 3 g/1.
- a control for the Accu-Chek ® EasyTM is prepared by dissolving per liter
- a control for the Accu-Chek ® EasyTM is prepared by dissolving per liter:
- Example II describes the addition of fixed red blood cells.
- Fixed red blood cells can be obtained by using conventional red blood cell fixing agents known in the art as, for example, aldehydes such as formaldehyde and glutaraldehyde, and imidinating agent such as dimethylsuberimidate or other chemical fixative agents. Any animal red blood cells can be utilized, but human and bovine red blood cells are preferred.
- Fixing of the red blood cells is readily accomplished by treating a suspension of the red blood cells with a sufficient concentration of the fixing agent.
- the amount of fixing agent added to the suspension of red blood cells will vary depending upon the number of cells in suspension being treated and the fixing agent employed. In the case of aldehyde and imidinating fixing agents, the concentration will usually vary from 0.004 to 1.0% by weight per 0.1xl0 1 /dL of red blood cells. A preferred concentration of redblood cells is about 0.1 to 0.3xl0 12 /dL.
- the reaction of the fixing agent with the red blood cells is allowed to proceed until their ability to metabolize glucose is completely inhibited. The fixing period necessary to achieve this result ordinarily takes about 24 to 48 hours.
- Figure 1 shows the reflectance values obtained at different time points and the effect of phosphate ions on the process at a constant glucose concentration. As the phosphate is increased, equilibrium is attained much quicker, resulting in higher reflectance values (less color) .
Abstract
A liquid glucose control solution includes water, a predetermined amount of glucose, phosphate as a reaction rate regulator and xanthan as a soluble gel. An alternative control solution may additionally include fixed red blood cells. Other materials such as a disinfectant may be added. The invention furthermore contemplates a process of making the liquid glucose control solution by mixing the required components together.
Description
Liquid Glucose Control Solution and Process of Making the Same
Background of the Invention
The present invention is directed generally to a glucose control solution for use in establishing the validity of dry reagent glucose test strips, and more particularly to a liquid glucose control suitable for use in glucose analyzer systems that give quantitative measures of glucose in blood or serum. The control solution includes water, a reaction-rate regulator, a gel which does not change viscosity with temperature, and glucose.
The level of glucose in the blood is determined by the amount of carbohydrate ingested and by available insulin. The diabetic may produce either excess insulin and have an abnormally low blood glucose level or, insufficient insulin which will result in an abnormally high level of blood glucose. Both circumstances lead to serious health problems for the diabetic. Monitoring the level of glucose in the blood is therefore important to the management of diabetes.
Dry reagent strips are widely used for detecting glucose in urine and blood. In general, such test strips comprise plastic strips provided at one end thereof with an absorbent paper portion impregnated with a detector system, e.g., an enzyme system and a color indicator compound which changes color when oxidized. The detector system is normally covered with a porous membrane filter. The change in r3»
color can be measured by comparing the strip to a color chart calibrated to various glucose concentrations. More recently, however, to enable the blood glucose level to be more accurately controlled, instruments have been developed to measure the color change in a reflectance photometer and thereby give quantitative results. One such instrument is commercially available from Diagnostic Laboratory Systems Division, Boehringer Mannheim corporation and is marketed under the name Accu-Chek®Easy™. This instrument is designed for use by diabetics so that they can monitor their blood glucose level.
Those skilled in the art know that controls or standards are required for these glucose analysis dry chemistry systems to assume that correct measurements are obtained. This need was met for most current systems with a stable blood glucose control which was the subject of U.S. Patent No. 4,729,959. Diabetics who self-test for blood glucose with the use of dry chemistry systems have concerns with the use of controls containing red blood cells. Prior art aqueous solutions of glucose do not give acceptable results in the Accu-Chek®Easy™ instrument.
Accordingly, a primary object of the invention is to provide an improved liquid glucose control solution.
Another object of the invention to provide a control solution with reaction kinetics providing rapid accurate readings stable over ninety seconds when used with a dry reagent strip.
Another object of the invention is to provide a control solution that produces reproducible readings
within a normal range of temperatures.
Summary of the Invention
The liquid glucose control solution of the present invention includes a stable liquid control solution including water, a predetermined amount of glucose, phosphate as an anionic component, and xanthan as a soluble gel. An alternative control solution may additionally include fixed red blood cells. Other materials such as a disinfectant may be mixed with the above four required components. Another aspect of the invention is a process of making the liquid glucose control solution by mixing the four required components together.
Brief Description of the Drawings
Figure 1 is a graph showing the effect of different phosphate concentrations on the reaction kinetics resulting from use of the present invention.
Description of the Preferred Embodiments
Whereas the liquid glucose control solution of the present invention is designed to operate with an instrument called the Accu-Chek®Easy™, it will also operate with many other instruments. The objectives of the control are to provide reaction kinetics comparable to blood; to defuse or chromatograph like blood, and to give responses that are not temperature dependent.
Any convenient method can be used to formulate the glucose reference control of the invention. One preferred procedure involves first
making up an aqueous glucose solution by adding glucose to distilled water followed by the addition of the essential phosphate and xanthan components and any optimal components such as a disinfectant. Fixed red cells may also be added to the control as in Ryan, U.S. Patent No. 4,729,959.
The water is used to create a reagent solution. With respect to the glucose, "predetermined" means that, prior to formulation of the actual reagent, a concentration of glucose has been selected. This concentration may vary as will be recognized by those skilled in the art. Ryan U.S. Patent No.4,729,959 discloses a range of from 2.22 mM/Lto 27.8 mM/L, but lower ranges to about 1.11 mM/L are possible. A typical range would be from about 3.33 mM/L to 16.7 mM/L. The units expressed are millimolar per liter.
Kinetics
Phosphate is included as a reaction rate regulator. It is desirable for the reaction to proceed rapidly and then plateau to a constant value. This pattern produces a result that is less time dependent. Thus, the meter can be read for example in 10 seconds or 60 seconds and the result will be the same.
Figure 1 shows the reflectance values obtained at different times and the effect of phosphate ions on the process. As the phosphate is increased, lower initial reflectance values (more color) are attained. However, when 40 mM/LP04 is used, there is a decoloration that occurs with time.
- 5 -
The ideal concentration is the 20 mM/LP04 where the reflectance is constant with time. The sample with no P04 produces such a slow reaction, that equilibrium is not reached until 70 seconds have passed. Accordingly, a phosphate concentration of about 5 to 35 mM/L may be used with about 10 to 30 being more preferred and about 20 mM/L being most preferred. These concentrations of phosphate are best for glucose concentrations of 2.8 mM/L - 13.9 mM/L. At higher concentrations of glucose, more phosphate is required and less at lower concentrations.
Other anions such as citrate or EDTA operate to produce rapid kinetics but are inferior to phosphate because they decolorize over time somewhat like the plot of the 40 mM/L concentration of phosphate in Figure 1.
Diffusion or Chromatography
To obtain an appropriate test, the glucose containing solution must move to the analysis system in a similar manner as blood. This requires that a thickening agent or gel be used. These agents include polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, dextran and bovine serum albumin. None of these agents provide any special characteristics except to make the solution viscous. In Kennamer, U.S. Patent No. 5,028,542, polystyrene sulphonate is claimed as a viscosity agent. As in the above, this agent simply increases viscosity. The gel that is used in the present invention is xanthan, a polysaccharide. This provides special characteristics to the product. Xanthan, unlike other gels, does not change viscosity with temperature. The viscosity of
the solution containing xanthan gum experiences almost no change with temperatures upto93°C (200,,F). A change in viscosity produces erratic values and variation in results with temperature. In addition, this gel produces uniform chromatography or diffusion of the control. This provides greater precision as shown by the data of the following Table I.
TABLE I Effect of xanthan gum has on the chromatography and precision of the Accu-Chek®Easy™
1.) Sample #1 fw/xanthan)
15.6 mM/L Na2HP04
4.7 mM/L NaH2P04
.lg/L Proclin 300
3.9g/L Xanthan Gum
8.33 mM/L Glucose
Accu-Chek®Easy™ Recovery .
S.D. C.V.
2.31 0.91
2~.) Sample #2 (w/o xanthan)
15.6 mM/L Na2HP04
4.7 mM/L NaH2P04
.lg/L Proclin 300
8.33 mM/L Glucose
Accu-Chek®Easv1MRecoverv
S.D. C.V.
21.63 10.44
Table I shows that both the standard deviation and coefficient of variation were about tenfold less in the series of tests with xanthan as
compared to the series of tests using the control solution without xanthan. Xanthan may be used in concentrations of about 1 to 5 g/1, more preferably 2 to 4 g/1 and optimally about 3 g/1.
Example I
A control for the Accu-Chek®Easy™ is prepared by dissolving per liter
15.6 mM Na2HP04
4.7 mM NaH?P04
3.00 gm xanthan
To this preparation is added the desired amount of glucose. After mixing to dissolve the components and gel, an appropriate disinfectant is added.
Example II
A control for the Accu-Chek®Easy™ is prepared by dissolving per liter:
15.6 mM Na2HP04 4.7 mM NaH?P04 3.00 gm xanthan 0.1xl212/dL fixed bovine red cells
To this preparation is added the desired amount of glucose. After mixing to dissolve the components and gel, an appropriate disinfectant is added.
Example II describes the addition of fixed red blood cells. Fixed red blood cells can be
obtained by using conventional red blood cell fixing agents known in the art as, for example, aldehydes such as formaldehyde and glutaraldehyde, and imidinating agent such as dimethylsuberimidate or other chemical fixative agents. Any animal red blood cells can be utilized, but human and bovine red blood cells are preferred.
Fixing of the red blood cells is readily accomplished by treating a suspension of the red blood cells with a sufficient concentration of the fixing agent. The amount of fixing agent added to the suspension of red blood cells will vary depending upon the number of cells in suspension being treated and the fixing agent employed. In the case of aldehyde and imidinating fixing agents, the concentration will usually vary from 0.004 to 1.0% by weight per 0.1xl01 /dL of red blood cells. A preferred concentration of redblood cells is about 0.1 to 0.3xl012/dL. In all cases, the reaction of the fixing agent with the red blood cells is allowed to proceed until their ability to metabolize glucose is completely inhibited. The fixing period necessary to achieve this result ordinarily takes about 24 to 48 hours.
Figure 1 shows the reflectance values obtained at different time points and the effect of phosphate ions on the process at a constant glucose concentration. As the phosphate is increased, equilibrium is attained much quicker, resulting in higher reflectance values (less color) .
Claims
1. A liquid glucose control solution for use in establishing the validity of dry reagent glucose test strips for indicating amounts of glucose in blood, said solution comprising, water; a predetermined amount of glucose; phosphate as a reaction rate regulator in a concentration of about 5 to 35 mM; and xanthan.
2. The liquid glucose control solution of claim 1 wherein the concentration of xanthan is about
2 to 4 g/1.
3. The liquid glucose control solution of claim 1 wherein the concentration of xanthan is about
3 g/i.
4. The liquid glucose control solution of claim 1 wherein the concentration of phosphate is about 10 to 30 mM/L.
5. The liquid glucose control solution of claim 1 wherein the concentration of phosphate is about 20 mM/L.
6. The liquid glucose control solution of claim 4 wherein said phosphate comprises sodium phosphate.
7. The liquid glucose control solution of claim 2 wherein said predetermined amount of glucose comprises,about 2.22 to 27.8 mM/L of glucose.
8. The liquid glucose control solution of claim 1 further comprising about 0.1 to 0.3xl012/dL red blood cells fixed with a fixing agent to render said red blood cells incapable of metabolizing glucose, the number of said fixed red blood cells being sufficient to provide a glucose reference control for glucose test strips in which the true value of glucose and the measured value is approximately the same.
9. The liquid glucose control solution of claim 8 wherein the red blood cell concentration is about 0.2 to 0.3xl012/dL.
10. The liquid glucose control solution of claim 8 wherein the red blood cell concentration is . about 0.3xl012/dL.
11. The liquid glucose control solution of claim 8 wherein the red blood cells are human red blood cells.
12. The liquid glucose control solution of claim 8 wherein the red blood cells are bovine red blood cells.
13. A process for making a liquid glucose control solution for use in establishing the validity of dry reagent glucose test strips, comprising mixing water, a predetermined amount of glucose, phosphate in a concentration of about 5 to 35 mM/L, and xanthan in a concentration of about 1 to 5 g/1.
14. The process of claim 13 further comprising mixing said xanthan in a concentration of about 2 to 4 g/1.
15. The process of claim 13 further comprising mixing said xanthan in a concentration of about 3 g/1.
16. The process of claim 13 further comprising mixing said phosphate xanthan in a concentration of about 10 to 30 mM/L.
17. The process of claim 16 further - comprising mixing said phosphate in a concentration of about 20 mM/L.
18. The process of claim 13 further comprising mixing about 0.1 to 0.3xl012dL red blood cells fixed with a fixing agent to render said red blood cells incapable of metabolizing glucose, the number of said fixed red blood cells being sufficient to provide a glucose reference control for glucose test strips in which the true value of glucose and the measured value is approximately the same.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87429992A | 1992-04-24 | 1992-04-24 | |
US07/874,299 | 1992-04-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993021928A1 true WO1993021928A1 (en) | 1993-11-11 |
Family
ID=25363442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/003799 WO1993021928A1 (en) | 1992-04-24 | 1993-04-21 | Liquid glucose control solution and process of making the same |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1993021928A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0730735A1 (en) * | 1993-11-12 | 1996-09-11 | Boehringer Mannheim Corporation | Glucose calibrator and control material for test strips |
US5858699A (en) * | 1994-04-05 | 1999-01-12 | Northern General Hospital Nhs Trust | Method to stabilize cell suspensions using aged heavy metal solution and paraformaldehyde |
US6197539B1 (en) * | 1993-07-05 | 2001-03-06 | Northern General Hospital N.H.S. Trust | Method for preparing a stabilized blood cell preparation using aged transition metal ion solution |
WO2006061607A1 (en) * | 2004-12-07 | 2006-06-15 | Honeywell Analytics Ag | Gas detection method and system |
EP2002841A1 (en) * | 2006-03-23 | 2008-12-17 | Senju Pharmaceutical Co., Ltd. | Ophthalmic composition comprising xanthan gum and glucose |
US7504020B2 (en) | 2002-10-31 | 2009-03-17 | Panasonic Corporation | Determination method for automatically identifying analyte liquid and standard solution for biosensor |
EP2267150A1 (en) | 2005-04-08 | 2010-12-29 | Bayer Healthcare LLC | Oxidizable species as an internal reference in control solutions for biosensors |
US8102517B2 (en) | 2004-12-13 | 2012-01-24 | Bayer Healthcare, Llc | Method of differentiating between blood and control solutions containing a common analyte |
US8337691B2 (en) | 2007-12-10 | 2012-12-25 | Bayer Healthcare Llc | Control markers for auto-detection of control solution and method of use |
US8696880B2 (en) | 2004-02-06 | 2014-04-15 | Bayer Healthcare Llc | Oxidizable species as an internal reference for biosensors and method of use |
EP3483598A1 (en) | 2005-09-30 | 2019-05-15 | Ascensia Diabetes Care Holdings AG | Gated voltammetry |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3920580A (en) * | 1973-07-12 | 1975-11-18 | Miles Lab | Liquid control solution |
US4572899A (en) * | 1982-07-07 | 1986-02-25 | Biotest-Serum-Institut Gmbh | Aqueous solution for suspending and storing cells, especially erthrocytes |
US4729959A (en) * | 1986-02-24 | 1988-03-08 | Streck Laboratories, Inc. | Glucose reference control for glucose test strips |
US5028542A (en) * | 1990-02-07 | 1991-07-02 | Boehringer Mannheim Corporation | Glucose measurement control reagent and method of making the same |
-
1993
- 1993-04-21 WO PCT/US1993/003799 patent/WO1993021928A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3920580A (en) * | 1973-07-12 | 1975-11-18 | Miles Lab | Liquid control solution |
US4572899A (en) * | 1982-07-07 | 1986-02-25 | Biotest-Serum-Institut Gmbh | Aqueous solution for suspending and storing cells, especially erthrocytes |
US4729959A (en) * | 1986-02-24 | 1988-03-08 | Streck Laboratories, Inc. | Glucose reference control for glucose test strips |
US5028542A (en) * | 1990-02-07 | 1991-07-02 | Boehringer Mannheim Corporation | Glucose measurement control reagent and method of making the same |
Non-Patent Citations (2)
Title |
---|
CHEMICAL ABSTRACTS, Vol. 113, issued 1990, HARADA et al., "Electron Microscopic Studies on Molecular Association in Gels of Curdlan and Other Polysaccharides in Food", see page 592, Abstract No. 189906r; & KOBE JOSHI DAIGAKU KIYO, 23(2):137-153. * |
G.O. PHILLIPS et al., "Gums and Stabilisers for the Food Industry 4", published 1987, by IRL PRESS (WASH. D.C.), pages 363-369. * |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6197539B1 (en) * | 1993-07-05 | 2001-03-06 | Northern General Hospital N.H.S. Trust | Method for preparing a stabilized blood cell preparation using aged transition metal ion solution |
US6197540B1 (en) | 1993-07-05 | 2001-03-06 | Northern General Hospital N.H.S. Trust | Preparation and stabilization of cells using aged transition metal solutions |
EP0730735A4 (en) * | 1993-11-12 | 2001-02-07 | Roche Diagnostics Corp | Glucose calibrator and control material for test strips |
EP0730735A1 (en) * | 1993-11-12 | 1996-09-11 | Boehringer Mannheim Corporation | Glucose calibrator and control material for test strips |
US5858699A (en) * | 1994-04-05 | 1999-01-12 | Northern General Hospital Nhs Trust | Method to stabilize cell suspensions using aged heavy metal solution and paraformaldehyde |
US7504020B2 (en) | 2002-10-31 | 2009-03-17 | Panasonic Corporation | Determination method for automatically identifying analyte liquid and standard solution for biosensor |
US10067082B2 (en) | 2004-02-06 | 2018-09-04 | Ascensia Diabetes Care Holdings Ag | Biosensor for determining an analyte concentration |
US9410917B2 (en) | 2004-02-06 | 2016-08-09 | Ascensia Diabetes Care Holdings Ag | Method of using a biosensor |
US8696880B2 (en) | 2004-02-06 | 2014-04-15 | Bayer Healthcare Llc | Oxidizable species as an internal reference for biosensors and method of use |
US7981364B2 (en) | 2004-12-07 | 2011-07-19 | Honeywell Analytics Ag | Gas detection method and system |
WO2006061607A1 (en) * | 2004-12-07 | 2006-06-15 | Honeywell Analytics Ag | Gas detection method and system |
US8102517B2 (en) | 2004-12-13 | 2012-01-24 | Bayer Healthcare, Llc | Method of differentiating between blood and control solutions containing a common analyte |
US8416398B2 (en) | 2004-12-13 | 2013-04-09 | Bayer Healthcare, Llc | Method of differentiating between blood and control solutions containing a common analyte |
US8681324B2 (en) | 2004-12-13 | 2014-03-25 | Bayer Healthcare, Llc | Method of differentiating between blood and control solutions containing a common analyte |
US8702926B2 (en) | 2005-04-08 | 2014-04-22 | Bayer Healthcare Llc | Oxidizable species as an internal reference in control solutions for biosensors |
US9244078B2 (en) | 2005-04-08 | 2016-01-26 | Bayer Healthcare Llc | Oxidizable species as an internal reference in control solutions for biosensors |
US9766198B2 (en) | 2005-04-08 | 2017-09-19 | Ascensia Diabetes Care Holdings Ag | Oxidizable species as an internal reference in control solutions for biosensors |
US8002965B2 (en) | 2005-04-08 | 2011-08-23 | Bayer Healthcare Llc | Oxidizable species as an internal reference in control solutions for biosensors |
EP2267150A1 (en) | 2005-04-08 | 2010-12-29 | Bayer Healthcare LLC | Oxidizable species as an internal reference in control solutions for biosensors |
EP3483598A1 (en) | 2005-09-30 | 2019-05-15 | Ascensia Diabetes Care Holdings AG | Gated voltammetry |
EP2002841A4 (en) * | 2006-03-23 | 2009-04-15 | Senju Pharma Co | Ophthalmic composition comprising xanthan gum and glucose |
CN101405009B (en) * | 2006-03-23 | 2011-04-13 | 千寿制药株式会社 | Ophthalmic composition comprising xanthan gum and glucose |
JP5244584B2 (en) * | 2006-03-23 | 2013-07-24 | 千寿製薬株式会社 | Ophthalmic composition containing xanthan gum and glucose |
EP2002841A1 (en) * | 2006-03-23 | 2008-12-17 | Senju Pharmaceutical Co., Ltd. | Ophthalmic composition comprising xanthan gum and glucose |
US7875271B2 (en) | 2006-03-23 | 2011-01-25 | Senju Pharmaceutical Co., Ltd. | Ophthalmic composition comprising xanthan gum and glucose |
US8716024B2 (en) | 2007-12-10 | 2014-05-06 | Bayer Healthcare Llc | Control solution for use in testing an electrochemical system |
US8871517B2 (en) | 2007-12-10 | 2014-10-28 | Bayer Healthcare Llc | Method of using a control solution and preparing for testing using the same |
US8337691B2 (en) | 2007-12-10 | 2012-12-25 | Bayer Healthcare Llc | Control markers for auto-detection of control solution and method of use |
US9933385B2 (en) | 2007-12-10 | 2018-04-03 | Ascensia Diabetes Care Holdings Ag | Method of using an electrochemical test sensor |
US10690614B2 (en) | 2007-12-10 | 2020-06-23 | Ascensia Diabetes Care Holdings Ag | Method of using an electrochemical test sensor |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3915647A (en) | Device for determining the concentration of a substance in a fluid | |
Mascini et al. | Urease coupled ammonia electrode for urea determination in blood serum | |
US5271815A (en) | Method for measuring glucose | |
Fogt et al. | Development and evaluation of a glucose analyzer for a glucose controlled insulin infusion system ((Biostator). | |
US5801059A (en) | Method for detecting total ketone bodies in urine | |
US3814668A (en) | Method and device for the semi-quantitative determination of glucose in aqueous fluids | |
JPS633260B2 (en) | ||
AU610412B2 (en) | Composition and method of assaying liquids for specific gravity | |
US5064615A (en) | Method and reagent for determining the ionic strength of specific gravity of aqueous liquids | |
WO1991012525A1 (en) | Glucose measurement control reagent | |
US4317879A (en) | Glucose analyzer membrane containing immobilized glucose oxidase | |
WO1993021928A1 (en) | Liquid glucose control solution and process of making the same | |
US3936357A (en) | Method and device for determining the concentration of a substance in a fluid | |
US3395082A (en) | Test composition device and method for detecting urea in aqueous fluids | |
Burnett et al. | IFCC recommended reference method for the determination of the substance concentration of ionized calcium in undiluted serum, plasma or whole blood | |
WO1994002842A1 (en) | Analytical method for the detection and measurement of paracetamol | |
DE69828319T2 (en) | METHOD AND APPARATUS FOR MEASURING BLOOD COAGULATION OR LYSIS WITH THE HELP OF VISCOSITY CHANGES | |
US3427225A (en) | Test composition,device and method for detecting urea in aqueous fluids | |
US4448889A (en) | Fluid analysis | |
CA1044583A (en) | Colorimetric assay for urea | |
JPH046907B2 (en) | ||
EP1307733B1 (en) | Creatinine sensor calibration | |
Stewart | Evaluation of a reagent-strip method for glucose in whole blood, as compared with a hexokinase method. | |
EP0730735B1 (en) | Glucose calibrator and control material for test strips | |
WO1995013536A9 (en) | Glucose control material for test strips |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |